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Abstract Cardiac troponin I(129^149) binds to the calcium
saturated cardiac troponin C/troponin I(1^80) complex at two
distinct sites. Binding of the first equivalent of troponin I(129^
149) was found to primarily affect amide proton chemical shifts
in the regulatory domain, while the second equivalent perturbed
amide proton chemical shifts within the D/E linker region.
Nitrogen-15 transverse relaxation rates showed that binding the
first equivalent of inhibitory peptide to the regulatory domain
decreased conformational exchange in defunct calcium binding
site I and that addition of the second equivalent of inhibitory
peptide decreased flexibility in the D/E linker region. No
interactions between the inhibitory peptide and the C-domain
of cardiac troponin C were detected by these methods
demonstrating that the inhibitory peptide cannot displace
cTnI(1^80) from the C-domain.
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1. Introduction
Cardiac muscle contraction is regulated by calcium depen-
dent interactions between members of the troponin complex
and other thin ¢lament proteins including actin and tropo-
myosin. The troponin complex consists of three proteins: tro-
ponin I (TnI) which inhibits the actomyosin Mg2-ATPase,
TnC which regulates TnI inhibition of the Mg2-ATPase, and
TnT which makes primary protein^protein contacts with tro-
pomyosin. TnC is the Ca2 binding component of the tropo-
nin complex that is required to confer Ca2 sensitivity on the
actin^myosin interaction. The cardiac isoforms of TnC and
TnI di¡er signi¢cantly from skeletal isoforms. In the cardiac
isoform of TnC, Ca2 binding site I is naturally inactive and
was found to undergo chemical exchange consistent with an
equilibrium between ‘closed’ and ‘open’ forms [1,2]. Calcium
binding to the isolated cTnC regulatory domain was shown
not to induce a structural opening similar to that seen in the
skeletal isoform [1,3]. The cardiac isoform of TnI is also
unique in that it contains an additional N-extension of ap-
proximately 32 residues. This extension contains two adjacent
serine residues that can be phosphorylated by cAMP depen-
dent protein kinase A [4].
Interactions between TnI and TnC have been recently re-
viewed [5^12]. Cardiac TnC and TnI are known to interact in
an antiparallel manner such that the C-domain of TnC inter-
acts with the N-domain of TnI [13]. The inhibitory region of
TnI plays a key regulatory role by inhibiting contraction at
low Ca2 concentrations [14]. Available biochemical data sup-
port models for interactions of TnIp, corresponding to cTnI
residues 129^149, with either both globular domains, the C-
domain, and/or the D/E linker region of TnC [7^9,15^19].
These models suggest exposure of hydrophobic patches on
each globular domain of cTnC upon the binding of Ca2
and interaction of an amphiphilic K-helical TnIp with the
exposed hydrophobic surface [20]. However, other regions of
cTnI have been shown to interact with the globular domains
of cTnC. In the intact TnIC complex, the C-terminal hydro-
phobic pocket of TnC is occupied with the N-domain of TnI
and may not be available for interaction with cTnIp [13,21^
23]. Cardiac TnI(147^163), a region of cTnI C-terminal to the
inhibitory region (cTnIp), has been shown to bind the isolated
cTnC regulatory domain and induce a structural opening sim-
ilar to that observed in sTnC upon Ca2 binding [8,9,24].
Further, in the cardiac isoform of TnC, exposure of the N-
domain hydrophobic pocket does not occur simultaneously
with Ca2 binding [3,25]. Binding of full length cTnI(1^211)
to Ca2 saturated cTnC has been shown to decrease £exibility
in the linker region between the N- and C-domains (Abbott,
unpublished), while the D/E linker remained £exible in the
presence of cTnI(1^80) [2]. Thus, the role of the inhibitory
region in Ca2 dependent regulation of muscle contraction
remains controversial and requires further investigation.
We have used chemical shift mapping, 15N relaxation ex-
periments, and 15N{1H}NOEs to further de¢ne the interaction
between cTnIp and cTnC in the troponin complex. As a con-
sequence of the size and complexity of the system, there are
presently no high resolution data on the intact system. In-
stead, structural studies on isolated domains and peptides
derived from these domains are being used to study the mo-
lecular details of this system. To complement our structural
and dynamic studies on the intact cTnIC complex and to
develop a more complete model system, we have studied the
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 2 7 1 - 0
*Corresponding author. Fax: (1)-513-558 847.
E-mail: rosevear@proto.med.uc.edu
Abbreviations: Tn, troponin; cTnC, recombinant cardiac troponin C
(desMet1-Ala2, Cys35Ser); sTnC, skeletal TnC; cTnI, cardiac tropo-
nin I; sTnI, skeletal troponin I; TnT, troponin T; cTnI(33^211),
recombinant cardiac troponin I corresponding to residues 33
through 211; cTnI(33^80), recombinant cardiac troponin I corre-
sponding to residues 33 through 80; cTnI(1^80), recombinant tropo-
nin I corresponding to the ¢rst 80 amino acid residues of cTnI;
NOE, nuclear Overhauser e¡ect; cTnIp, synthetic N-acetyl-
TQKIYDLRGKFKRPTLRRVRI-amide, corresponding to mouse
cTnI(129^149); cTnIC, cardiac TnC/TnI binary complex; R2, 15N
transverse relaxation rates
FEBS 23413 2-3-00
FEBS 23413FEBS Letters 469 (2000) 168^172
binding of cTnIp to Ca2 saturated cTnC/cTnI(1^80). Chem-
ical shift perturbation mapping and 15N transverse relaxation
values identify two binding sites for the inhibitory peptide,
cTnIp, on the cTnC/cTnI(1^80) complex. Binding of one
equivalent of cTnIp to form a cTnC/cTnI(1^80)/cTnIp com-
plex reduced mobility in defunct Ca2 binding site I. Binding
of the second equivalent of cTnIp was found to result in
decreased £exibility within the D/E linker region. However,
15N{1H} heteronuclear NOE values indicate that some fast
picosecond motion persists in the linker region in the presence
of two equivalents of cTnIp.
2. Materials and methods
2.1. Proteins and peptides
The synthetic peptide N-acetyl-TQKIYDLRGKFKRPTLRRVRI-
amide, corresponding to mouse cTnIp, was synthesized by Protein
Express (Cincinnati, OH) and the sequence con¢rmed by mass spec-
troscopy. The purity of the peptide was con¢rmed by high perform-
ance liquid chromatography. 15N and 2H labeled cTnC and cTnI(1^
80) were puri¢ed and complex formation carried out as previously
described [2]. For NMR experiments, cTnC/cTnI(1^80) complex was
prepared at 1.0 mM concentration in 10% 2H2O, 20 mM Tris-d11
bu¡er (pH 6.8), 150 mM potassium chloride, 10 mM Ca2, 5 mM
dithiothreitol [2]. Protein concentrations for cTnC were determined by
UV and Bradford analysis. Cardiac TnI concentrations were deter-
mined by the bicinchoninic acid assay (Pierce, Rockford, IL). Amino
acid analysis was used to calibrate the colorimetric methods and con-
¢rm concentrations. Synthetic peptide concentrations were determined
by amino acid analysis. Complete EDTA-free protease inhibitor cock-
tail (Boehringer Mannheim, Germany) was added to the NMR sam-
ples to prevent proteolysis during long NMR experiments.
2.2. NMR spectroscopy
All experiments were carried out on Varian Inova 600 or 800 MHz
spectrometers. Amide 1H and 15N resonances for cTnC in the Ca2
saturated cTnC/cTnI(1^80) complex have previously been assigned by
means of heteronuclear triple resonance NMR experiments [26]. Ni-
trogen-15 relaxation experiments were performed and processed as
described by Gaponenko et al. [2] using the CURVEFIT software
[27]. Spectra were referenced to an external 2,2-dimethyl-2-silapen-
tane-5-sulfonate, sodium salt standard.
3. Results
3.1. Mapping of interactions between cTnC/cTnI(1^80) and
cTnIp
Previously, we have shown that the N-domain of cTnI in-
teracts with the C-domain of cTnC [13,21]. In addition, the
cardiac speci¢c amino-terminus, consisting of residues 1^32,
was found to interact with the regulatory domain of cTnC
and decrease chemical exchange, presumably changing the
dynamic equilibrium between ‘open’ and ‘closed’ conforma-
tions [2]. In view of these recent structural data, the proposed
binding site for cTnIp on cTnC warrants further investigation.
We have studied the binding of the well known cardiac inhib-
itory peptide cTnIp, or cTnI(129^149), to the Ca2 saturated
[15N, 2H]cTnC/cTnI(1^80) complex. Assignments in the ter-
nary complex, [15N, 2H]cTnC/cTnI(1^80)/cTnIp, were made
by comparison with those obtained in the [15N, 2H]cTnC/
cTnI(1^80) complex [26] and con¢rmed by analysis of sequen-
tial NOEs in NOESY-HSQC spectra (data not shown). The
majority of cTnC amide resonances, upon titration of the
cTnC/cTnI(1^80) complex with cTnIp, were in fast exchange
with a few resonances in the slow to intermediate exchange
regime. Amide resonances found to be in slow to intermediate
exchange were Val29, Ala31, Gly34, and Asp73. These resi-
dues have previously been observed to be in slow exchange in
the intact cTnC/cTnI complex (Abbott, unpublished).
Chemical shift perturbations were used to monitor cTnIp
interactions in the [15N, 2H]cTnC/cTnI(1^80) complex. Fig. 1
shows chemical shift changes for amide 1H resonances of
[15N, 2H]cTnC bound to cTnI(1^80) observed in the presence
of 1.4 equivalents of cTnIp. The largest amide 1H chemical
shifts were observed in defunct site I and active Ca2 binding
site II suggesting cTnIp binds to the regulatory domain in the
cTnC/cTnI(1^80) complex. Small amide 1H chemical shifts
were also observed for residues 66 and 74 in helix D as well
as residues 99 and 102 in helix E, surrounding the £exible
linker region. No signi¢cant amide 1H chemical shift changes
were found in the C-domain (Fig. 1A). Addition of another
1.3 equivalents of cTnIp to form a 1:1:2.7 cTnC/cTnI(1^80)/
cTnIp solution resulted in additional amide 1H chemical shift
changes in helices D and E (Fig. 1B). Speci¢cally, chemical
shift changes were observed in the C-terminus of helix D, the
N-terminus of helix E, as well as in residue 92 within the
linker region (Fig. 1B). The linker region corresponds to res-
idues 83^93 [26]. Again, no signi¢cant chemical shift changes
were observed in the C-domain. Thus, chemical shift changes
could be used to map a second cTnIp binding site to the D/E
linker region of cTnC.
Fig. 1. Amide proton chemical shift di¡erences between Ca2 satu-
rated [15N, 2H]cTnC/cTnI(1^80) and cTnC/cTn(1^80)/cTnIp at stoi-
chiometric ratios of 1:1:1.4 (A) and 1:1:2.6 (B). The horizontal line
represents the average chemical shift di¡erence plus one S.D.,
0.004 þ 0.004 ppm in A, and 0.006 þ 0.006 ppm in B. Filled dia-
monds mark residues for which resonance assignments in 1H-15N
correlation spectrum could be not con¢rmed due to a lack of se-
quential NOEs in NOESY-HSQC spectra. These residues are 1, 2,
3, 6, 17, 20, 24, 28, 36, 37, 38, 39, 41, 44, 47, 58, 62, 64, 65, 75, 83,
85, 97, 101, 118, 132, and 136. Residues 52 and 54, also marked
with black diamonds, are prolines. Cross-peaks for 32, 81, 84, and
150, marked by open triangles, are broadened beyond detection in
1H-15N correlation spectra of cTnC/cTnI(1^80) or cTnC/cTnI(1^80)/
cTnIp at both concentrations of cTnIp. The resonance for residue
51, also indicated by an open triangle, is broadened only at high
concentrations of cTnIp.
FEBS 23413 2-3-00
M.B. Abbott et al./FEBS Letters 469 (2000) 168^172 169
3.2. Dynamic consequences of cTnIp binding to
cTnC/cTnI(1^80)
Transverse relaxation rates (R2) and 15N{1H} heteronucle-
ar NOE values were used to study the interaction of cTnIp
with the binary cTnC/TnI(1^80) complex. 15N R2 values
were measured for [15N, 2H]cTnC/cTnI(1^80) and for
[15N, 2H]cTnC/cTnI(1^80)/cTnIp samples having either ap-
proximately one or two equivalents of cTnIp bound (Fig. 2).
15N R2 values for the cTnC/cTnI(1^80) complex, taken from
Gaponenko et al. [2], are included for comparison. 15N R2
values depend on the rotational correlation time of the com-
plex in solution, as well as chemical exchange and cross-relax-
ation. The presence of one equivalent of cTnIp dramatically
increases 15N R2 values in inactive calcium binding site I,
consistent with reduced millisecond motion of this previously
£exible loop. Low 15N R2 values persist for residues within the
D/E linker region, suggesting £exibility in this region is un-
a¡ected by cTnIp. The average 15N R2 values for the N- and C-
domains in [15N, 2H]cTnC/cTnI(1^80) and [15N, 2H]cTnC/
cTnI(1^80)/cTnIp are similar indicating uniform tumbling
across the molecule in both complexes (Fig. 2B,C). As ex-
pected, 15N R2 values decrease at the N- and C-termini of
cTnC for the two complexes (Fig. 2A,B). Higher average
15N R2 values in the [15N, 2H]cTnC/cTnI(1^80)/cTnIp com-
plex may be due to the increased molecular mass or a more
extended conformation resulting in a larger rotational corre-
lation time for this complex.
Addition of the second equivalent of cTnIp, to form a 1:1:2
cTnC/cTnI(1^80)/cTnIp complex, increased 15N R2 values for
the D/E linker region of cTnC suggesting that conformational
£exibility in this region is considerably reduced by binding the
second equivalent of cTnIp (Fig. 2C). In addition to the loss
of £exibility in the linker region, a signi¢cant loss in £exibility
was observed in both the N- and C-termini of cTnC (Fig. 2C).
Some conformational £exibility was still observed in defunct
Ca2 binding site I as judged by a decrease in 15N R2 values
for residues G34 and G42 compared with the average 15N R2
value, 29.2 þ 3.4 s31 (Fig. 2C). The average 15N R2 value for
this complex was smaller than the average 15N R2 value for
the 1:1:1 cTnC/cTnI(1^80)/cTnIp complex, suggesting a
shorter rotational correlation time, consistent with a more
compact structure for the complex and loss of mobility at
Fig. 2. Plots of 15N transverse relaxation rates, R2 (b) for Ca2 sat-
urated [15N, 2H]cTnC bound to cTnI(1^80) (A) and to cTnI(1^80)/
cTnIp with a ratio of 1:1.4 (B) and to cTnI(1^80)/cTnIp with a
ratio of 1:2.6 (C). Residues 21, 22, 27, 33, 48, 50, 56, 57, 86, 60,
95, 96, 100, 109, 115, 120, 121, 123, 126, 131, 144, 147, and 154
were excluded from the analysis due to peak overlap in the 1H-15N
correlation spectra of cTnC in the presence of cTnI(1^80) and
cTnIp(129^149). Cross-peaks for 29, 30, 71, 74, and 80 were too
broad for reliable R2 determination. Values for Ca2 saturated
[15N, 2H]cTnC bound to cTnI(1^80) were taken from Gaponenko
et al. [2].
Fig. 3. 15N{1H} heteronuclear NOE values for Ca2 saturated
[15N, 2H]cTnC bound to cTnI(1^80) (A) and Ca2 saturated
[15N, 2H]cTnC bound to cTnI(1^80) and cTnIp at a ratio of 1:1:1.4
(B) and Ca2 saturated [15N, 2H]cTnC bound to cTnI(1^80) and
cTnIp at a stoichiometry of 1:1:2.6 (C). Accurate measurement of
15N{1H} NOE for residues 29, 30, 32, 74, 77, 93, 102, and 159 was
not possible in the cTnC/cTnI(1^80) at one equivalent of cTnIp (B).
At higher concentrations of cTnIp, accurate measurement of
15N{1H} NOE for residues 51, 80, 81, 84, and 159 also became im-
possible (C).
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the N- and C-termini of cTnC in the presence of the second
equivalent of cTnIp.
To further investigate dynamic consequences of binding
cTnIp to the binary complex, on the picosecond time scale,
15N{1H} heteronuclear NOEs for 15N perdeuterated cTnC/
cTnI(1^80) and cTnC/cTnI(1^80)/cTnIp with approximately
one and two equivalents of cTnIp bound were compared
(Fig. 3A^C). Lower heteronuclear NOE values are observed
in inactive calcium binding site I and calcium binding site II
as well as the linker region of cTnC bound to cTnI(1^80).
Thus, these regions are expected to have rapid internal mo-
tions. Addition of cTnIp to the binary complex does not ap-
pear to greatly alter the magnitude of 15N{1H} heteronuclear
NOE values in the two globular domains or in the D/E linker
region at either cTnIp concentration (Fig. 3B,C). These results
suggest relatively uniform motion on a nanosecond time scale
across both domains of cTnC in the ternary complex.
Both chemical shift perturbations and 15N R2 changes are
consistent with two binding sites for cTnIp in the cTnC/
cTnI(1^80) complex. The ¢rst equivalent of cTnIp results in
chemical shift changes and increased 15N R2 values in the
regulatory domain of cTnC. The second equivalent of cTnIp
results in chemical shift perturbations and decreased £exibility
in both the linker region and the N- and C-termini of cTnC.
Lower average 15N R2 values suggest a more compact shape
for the complex with two equivalents of cTnIp bound. No
chemical shift changes or perturbation of dynamic parameters
were observed in the C-domain of cTnC. Taken together, the
data clarify existing biochemical data and demonstrate possi-
ble pitfalls of using peptides to model interactions of intact
proteins.
4. Discussion
Localization of interactions between cTnIp and cTnC is
crucial to understanding the mechanism of the Ca2 triggered
troponin molecular switch. In our e¡orts to understand the
interactions between intact cTnC and cTnI, we chose to map
the structural and dynamic consequences of cTnIp binding to
cTnC/cTnI(1^80). The binary cTnC/cTnI(1^80) complex was
used since it is known that cTnI residues 33^80 interact in the
C-domain hydrophobic pocket of cTnC [13,21]. In the absence
of the N-domain of cTnI, cTnIp has been shown to bind to
the C-domain of cTnC [19]. To determine if cTnIp could still
bind the C-domain of cTnC in the presence of the N-domain
of cTnI, cTnIp was titrated into the binary cTnC/cTnI(1^80)
complex. Two cTnIp binding sites were identi¢ed by chemical
shift perturbations and altered dynamics in discrete regions
of cTnC. Interactions of cTnIp that a¡ect defunct Ca2 bind-
ing site I did not preclude the observation of multiple
NMR detectable conformers for the regulatory domain. Ad-
dition of a second equivalent of cTnIp induced chemical shift
changes in residues at the end and at the beginning of helices
D and E, respectively (Fig. 1). Interactions of cTnIp with
the D/E linker region resulted in a decrease in £exibility with-
in this region as judged by measured 15N transverse relaxa-
tion rates (Fig. 2). Weaker binding of cTnIp to the D/E
linker region may re£ect the entropic cost of restricting £ex-
ibility within this region. No evidence for cTnIp inter-
acting with the C-domain of cTnC in the complex was ob-
served.
Under our conditions, cTnIp cannot displace cTnI(1^80)
from the C-domain of cTnC as would be predicted by the
‘TnI switching’ model [28,29]. The TnI switching model pos-
tulates that residues 33^80 of cTnI (corresponding to skeletal
TnI residues 1^40) and the inhibitory region of cTnI compete
for the C-domain of cTnC, with Ca2 saturation favoring the
binding of the inhibitory region [9,12,28,29]. A combination
of chemical shift mapping and relaxation studies has now
demonstrated that the inhibitory peptide can bind to both
the regulatory domain and the D/E linker region but not
the C-domain of cTnC in the presence of cTnI(1^80) (Fig.
4). Cross-linking data for sTnIp binding to sTnC also support
interactions for TnIp with both the regulatory domain and the
linker region of TnC [16,30,31]. The recent NMR structure of
cTnI(147^163) bound to the isolated regulatory domain of
cTnC [24] suggests that in the intact cTnC/cTnI complex,
cTnIp may interact with the D/E linker region of cTnC. In
the X-ray crystallographic structure of sTnC bound to
sTnI(1^47), the linker region of TnC is unwound and bent
by 90‡ between the D and E helices [22]. This region corre-
sponds to residues Ser89-Lys90-Gly91-Lys92-Thr93 in the car-
diac isoform and is the region, as identi¢ed by chemical shift
mapping and relaxation data, that binds the second equivalent
of cTnIp in the Ca2 saturated cTnC/cTnI(1^80)/cTnIp com-
plex. Spin labeling studies on cTnC/cTnI(33^211) complex are
consistent with a decrease in £exibility of the linker region in
cTnC upon complex formation with cTnI [23]. Recent detailed
dynamic studies of the cTnC/cTnI(1^211) complex also indi-
cate reduced £exibility in the linker region of cTnC compared
to the cTnC/cTnI(1^80) complex (Abbott, unpublished).
These data suggest that a region of cTnI between residues
80 and 211, possibly corresponding to cTnIp, restricts the
mobility of the linker region in the intact cTnC/cTnI complex.
Fig. 4. Summary of proposed cTnC and cTnI interactions. Roman
numerals indicate the Ca2 binding sites in cTnC. Site I (naturally
inactive) and site II are located in the N-domain, while sites III and
IV lie in the C-domain. The two globular domains are connected by
the D/E linker (residues 83^93). Functionally signi¢cant regions of
cTnI are shaded. The cardiac speci¢c N-terminus of cTnI consists
of residues 1^32. Residues 33^80 comprise the ¢rst cTnC binding
site (dark gray), while residues 147^163 constitute the second cTnC
binding site (dark gray). The inhibitory region (light gray) includes
residues 129^147. Arrows represent proposed interactions. In the ab-
sence of bound Ca2 in the regulatory domain (A), residues 33^80
of cTnI interact with the C-domain of cTnC [21]. Upon Ca2 bind-
ing to the regulatory domain (B), cTnI residues 147^163 interact
with the N-domain of cTnC [24]. The inhibitory region of cTnI,
corresponding to residues 129^147, may interact with the D/E link-
er. No evidence for interactions between cTnIp and the C-domain
of cTnC was found in the presence of cTnI(1^80), suggesting that
the inhibitory region does not compete with the cTnI N-domain
(residues 33^80) for binding the cTnC C-domain, as proposed by
the TnI switching model [9,12,28,29].
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Thus, the physiologically relevant cTnIp binding site on cTnC
may be the D/E linker region.
Taken together, the available data for the cardiac TnIC
interaction are more consistent with the model proposed by
Maeda’s group for the skeletal isoforms [22]. In this model,
the N-domain for cTnI comprising residues 33^80 (corre-
sponding to residues 1^47 in the skeletal isoform) are bound
to the C-domain of TnC in both the presence and absence of
Ca2 at the regulatory site (Fig. 4). The inhibitory region of
TnI, residues 129^149 in the cardiac isoform (corresponding
to residues 96^115 in the skeletal isoform), would interact
with the D/E linker region in TnC. The ‘second Ca2 depen-
dent interaction site’ [9] of TnI corresponding to residues 147^
163 for the cardiac isoform (residues 115^131 in the skeletal
isoform) would bind to the N-domain of TnC in a Ca2 de-
pendent manner. Regions of TnI C-terminal to this region are
believed to make interactions with other thin ¢lament pro-
teins. Modulation of the interaction between the ‘second
Ca2 dependent interaction site’ and the regulatory domain
of cTnC by intracellular calcium £ux may ‘pull’ the adjacent
inhibitory region of cTnI away from actin, relieving the inhi-
bition of muscle contraction.
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